# Celcuity Inc.: overview CELC · Nasdaq · CIK 1603454 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/celc.md) · [Financials](/companies/celc/financials.md) · [Filings](/companies/celc/filings.md) · [Insiders](/companies/celc/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.70)](/filings/0001493152-25-022401.md) | not reported | [(0.86)](/filings/0001493152-26-023180.md) | [(1.04)](/filings/0001193125-26-349608.md) | [(0.92)](/filings/0001493152-25-022401.md) | not reported | [(0.97)](/filings/0001493152-26-023180.md) | [(1.44)](/filings/0001193125-26-349608.md) | | Free cash flow | $m | [(20.6) d](/filings/0001493152-25-022401.md) | [(27.8) d](/filings/0001493152-26-012801.md) | [(35.9)](/filings/0001493152-26-023180.md) | [(36.3) d](/filings/0001193125-26-349608.md) | [(44.9) d](/filings/0001493152-25-022401.md) | [(36.5) d](/filings/0001493152-26-012801.md) | [(55.3)](/filings/0001493152-26-023180.md) | [(55.5) d](/filings/0001193125-26-349608.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.21)](/filings/0001493152-22-007560.md) | [(2.64)](/filings/0001493152-24-011549.md) | [(2.69)](/filings/0001641172-25-001826.md) | [(2.83)](/filings/0001493152-26-012801.md) | [(3.79)](/filings/0001493152-26-012801.md) | | Free cash flow | $m | [(20.4)](/filings/0001493152-23-008724.md) | [(36.2)](/filings/0001493152-24-011549.md) | [(53.9)](/filings/0001641172-25-001826.md) | [(83.7)](/filings/0001493152-26-012801.md) | [(154)](/filings/0001493152-26-012801.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/celc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $828.2m | 7,915,792 | | Unchanged | | [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $355.7m | 3,400,000 | | Added +25,000 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $345.8m | 3,304,903 | | Added +265,282 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $334.5m | 3,197,200 | | Added +70,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $315.8m | 3,018,785 | | Added +307,253 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $204.6m | 1,955,304 | | Added +436,599 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $196.1m | 1,874,137 | | Added +91,243 | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $179.0m | 1,710,561 | | Reduced −575,000 | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $178.3m | 1,704,318 | | Added +419,940 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $153.9m | 1,471,307 | | Added +756,978 | ## Recent filings [All 535 filings](/companies/celc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-02 | 12:05 ET | [8-K](/filings/0001193125-26-411297.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-411297 | | 2026-09-30 | 12:05 ET | [8-K](/filings/0001193125-26-408353.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-408353 | | 2026-08-26 | 12:35 ET | [8-K](/filings/0001193125-26-365975.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-365975 | | 2026-08-13 | 21:15 ET | [10-Q](/filings/0001193125-26-349608.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349608 | | 2026-08-13 | 20:15 ET | [8-K](/filings/0001193125-26-349227.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349227 | | 2026-07-16 | 21:51 ET | [SCHEDULE 13D/A](/filings/0001104659-26-084327.md) | Ownership report, active investor, amended | 0001104659-26-084327 | | 2026-07-15 | 20:05 ET | [8-K/A](/filings/0001493152-26-033357.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-033357 | | 2026-07-15 | 21:39 ET | [8-K](/filings/0001493152-26-033223.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-033223 | | 2026-06-08 | 20:10 ET | [8-K](/filings/0001493152-26-027717.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-027717 | | 2026-06-02 | 12:10 ET | [8-K](/filings/0001493152-26-026761.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-026761 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-012801.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1603454 - Tickers: CELC - Exchange: Nasdaq - SIC code: 8071 Services-Medical Laboratories - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.